Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle

被引:5
|
作者
Johnson, Carys S. [1 ,2 ]
Williams, Matthew [1 ,2 ]
Sham, Kendig [1 ,2 ]
Belluschi, Serena [1 ,2 ]
Ma, Wenjuan [1 ,2 ]
Wang, Xiaonan [1 ,2 ]
Lau, Winnie W. Y. [1 ,2 ]
Kaufmann, Kerstin B. [4 ]
Krivdova, Gabriela [4 ]
Calderbank, Emily F. [1 ,2 ]
Mende, Nicole [1 ,2 ]
McLeod, Jessica [4 ]
Mantica, Giovanna [1 ,2 ]
Li, Juan [1 ,2 ]
Grey-Wilson, Charlotte [1 ,2 ]
Drakopoulos, Michael [1 ,2 ]
Basheer, Shaaezmeen [1 ,2 ]
Sinha, Shubhankar [1 ,2 ]
Diamanti, Evangelia [1 ,2 ]
Basford, Christina [3 ]
Wilson, Nicola K. [1 ,2 ]
Howe, Steven J. [3 ]
Dick, John E. [4 ]
Gottgens, Berthold [1 ,2 ]
Green, Anthony R. [1 ,2 ]
Francis, Natalie [3 ,5 ]
Laurenti, Elisa [1 ,2 ]
机构
[1] Univ Cambridge, Cambridge Stem Cell Inst, Wellcome & Med Res Council, Cambridge, England
[2] Univ Cambridge, Dept Haematol, Cambridge CB2 0AW, England
[3] GlaxoSmithKline, Cell Proc Dev Cell & Gene Therapy, Stevenage, England
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Kings Coll London, Dept Gene Therapy & Regenerat Med, London, England
基金
英国科研创新办公室; 英国医学研究理事会; 英国惠康基金;
关键词
SELF-RENEWAL; PROTEIN-SYNTHESIS; CORD BLOOD; PROGENITORS; GENERATION; QUIESCENCE; MAINTAINS; EXPANSION; CAPACITY; PROMOTES;
D O I
10.1182/blood.2023021426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Loss of long-term hematopoietic stem cell (LT-HSC) function ex vivo hampers the success of clinical protocols that rely on culture. However, the kinetics and mechanisms through which this occurs remain incompletely characterized. In this study, through time-resolved single-cell RNA sequencing, matched in vivo functional analysis, and the use of a reversible in vitro system of early G1 1 arrest, we defined fi ned the sequence of transcriptional and functional events that occur during the fi rst ex vivo division of human LT-HSCs. We demonstrated that the sharpest loss in LT-HSC repopulation capacity happens early on, between 6 and 24 hours of culture, before LT-HSCs commit to cell cycle progression. During this time window, LT-HSCs adapt to the culture environment, limit the global variability in gene expression, and transiently upregulate gene networks involved in signaling and stress responses. From 24 hours, LT-HSC progression past early G1 1 contributes to the establishment of differentiation programs in culture. However, contrary to the current assumptions, we demonstrated that the loss of HSC function ex vivo is independent of cell cycle progression. Finally, we showed that targeting LT-HSC adaptation to culture by inhibiting the early activation of JAK/ STAT signaling improves HSC long-term repopulating function ex vivo. Collectively, our study demonstrated that controlling early LT-HSC adaptation to ex vivo culture, for example, via JAK inhibition, is critically important to improve HSC gene therapy and expansion protocols.
引用
收藏
页码:729 / 741
页数:13
相关论文
共 50 条
  • [41] Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
    Zeng, Jing
    Nguyen, My Anh
    Liu, Pengpeng
    Silva, Lucas Ferreira da
    Levesque, Sebastien
    Lin, Linda Y.
    Justus, David G.
    Petri, Karl
    Clement, Kendell
    Porter, Shaina N.
    Verma, Archana
    Neri, Nola R.
    Rosanwo, Tolulope
    Ciuculescu, Marioara-Felicia
    Abriss, Daniela
    Mintzer, Esther
    Maitland, Stacy A.
    Demirci, Selami
    Cha, Hye Ji
    Orkin, Stuart H.
    Tisdale, John F.
    Williams, David A.
    Zhu, Lihua Julie
    Pruett-Miller, Shondra M.
    Pinello, Luca
    Joung, J. Keith
    Pattanayak, Vikram
    Manis, John P.
    Armant, Myriam
    Pellin, Danilo
    Brendel, Christian
    Wolfe, Scot A.
    Bauer, Daniel E.
    CELL STEM CELL, 2025, 32 (02)
  • [42] In Vivo Hematopoietic Stem Cell Transduction
    Richter, Maximilian
    Stone, Daniel
    Miao, Carol
    Humbert, Olivier
    Kiem, Hans-Peter
    Papayannopoulou, Thalia
    Lieber, Andre
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (05) : 771 - +
  • [43] Adhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo culture
    Huygen, S
    Giet, O
    Artisien, V
    Di Stefano, I
    Beguin, Y
    Gothot, A
    BLOOD, 2002, 100 (08) : 2744 - 2752
  • [44] STEM CELL ENGINEERING TOWARDS THE OPTIMIZATION OF THE EX-VIVO EXPANSION OF HUMAN HEMATOPOIETIC STEM/PROGENITOR CELLS FOR CELLULAR THERAPIES
    da Silva, C. L.
    Andrade, P. Z.
    Soure, A. M.
    Santos, F. D.
    Almeida-Porada, G.
    Cabral, J. S.
    CYTOTHERAPY, 2014, 16 (04) : S60 - S60
  • [45] Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells
    Shin, Dong-Yeop
    Huang, Xinxin
    Gil, Chang-Hyun
    Aljoufi, Arafat
    Ropa, James
    Broxmeyer, Hal E.
    STEM CELLS, 2020, 38 (11) : 1454 - 1466
  • [46] Advances in hematopoietic stem cell culture
    Audet, J
    Zandstra, PW
    Eaves, CJ
    Piret, JM
    CURRENT OPINION IN BIOTECHNOLOGY, 1998, 9 (02) : 146 - 151
  • [47] Co-transplantation of ex-vivo culture-expanded human mesenchymal stem cells and allogeneic hematopoietic stem cell transplantation - Report of 12 cases
    Kim, JH
    Jeong, SH
    Kang, SY
    Jeong, JH
    Park, JS
    Choi, JH
    Lim, HY
    Kim, HS
    Kim, MK
    Park, SJ
    Kim, YJ
    Kim, HS
    BLOOD, 2002, 100 (11) : 183B - 184B
  • [48] Ex vivo generated mesenchymal cells as adjunct to hematopoietic stem cell transplantation.
    Carlo-Stella, C
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 139 - 139
  • [49] Development of an ex vivo hematopoietic stem cell gene therapy for frontotemporal dementia (FTD)
    Ciervo, Y.
    Rigoni, P.
    Bologna, N.
    Accardo, M.
    Santinon, G.
    Recchi, C.
    Milazzo, R.
    Biffi, A.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A31 - A31
  • [50] Development of an Ex Vivo Hematopoietic Stem Cell Gene Therapy for Frontotemporal Dementia (FTD)
    Ciervo, Yuri
    Rigoni, Pietro
    Bologna, Nadia
    Accardo, Massimo
    Santinon, Giulia
    Recchi, Chiara
    Milazzo, Rita
    Biffi, Alessandra
    MOLECULAR THERAPY, 2024, 32 (04) : 540 - 540